Jun Wada, Kazumasa Kawashima, Michio Onizawa, Naohiko Gunji, Yu Watahiki, Chiharu Sakuma, Mai Murakami, Tomoaki Mochimaru, Shunsuke Miura, Hiromasa Ohira
{"title":"Ulcerative Colitis with Acute Pericarditis after Dose Escalation of Mesalazine.","authors":"Jun Wada, Kazumasa Kawashima, Michio Onizawa, Naohiko Gunji, Yu Watahiki, Chiharu Sakuma, Mai Murakami, Tomoaki Mochimaru, Shunsuke Miura, Hiromasa Ohira","doi":"10.2169/internalmedicine.4655-24","DOIUrl":null,"url":null,"abstract":"<p><p>Mesalazine-induced pericarditis is rare, and most cases occur at the time of treatment initiation. A 30-year-old man with ulcerative colitis who had experienced remission for 2 years with mesalazine 2,000 mg/day subsequently experienced relapse. Therefore, the mesalazine dose was increased to 4,000 mg. Thereafter, hematochezia improved, but anterior chest pain developed. Chest radiography revealed marked cardiac dilation (cardiothoracic ratio, 63%) and echocardiography revealed pericardial effusion. Adverse events associated with mesalazine should be carefully monitored, not only at the time of treatment initiation but also after dose escalation.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"2165-2169"},"PeriodicalIF":1.0000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.4655-24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Mesalazine-induced pericarditis is rare, and most cases occur at the time of treatment initiation. A 30-year-old man with ulcerative colitis who had experienced remission for 2 years with mesalazine 2,000 mg/day subsequently experienced relapse. Therefore, the mesalazine dose was increased to 4,000 mg. Thereafter, hematochezia improved, but anterior chest pain developed. Chest radiography revealed marked cardiac dilation (cardiothoracic ratio, 63%) and echocardiography revealed pericardial effusion. Adverse events associated with mesalazine should be carefully monitored, not only at the time of treatment initiation but also after dose escalation.
期刊介绍:
Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine.
Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.